

## Index

### a

Ac-Asp-Glu-Val-Asp-Cys(StBu)-Lys-CBT  
169

acetyl protected short peptides 129

Ac-Lys-Asp-Glu-Asp-Val-Cys(StBu)-CBT  
169

additive manufacturing 241, 242, 296,  
300, 317

adipose-derived stem cell (ADSC)  
329–330, 340–342

aldehyde-modified HA (HA-ALD) 44

alkaline phosphatase (ALP) 43, 75, 77,  
112, 138, 162, 164, 165, 177, 180,  
183, 184, 186, 187, 190, 315, 317

alkaline phosphatase (ALPL) 164, 165

2-aminoethyl methacrylate  
(AEMA)-modified HA 221

amyloid fibrils 109

anisotropic diamagnetism 108

anisotropic monolayer model 119

anisotropy 98, 108, 109, 111–113, 115

antibiofouling 207

anticancer agent 137, 175

aromatic dipeptide 99, 105

artificial wound exudate (AWE) 207

atomic force microscopy (AFM) 3, 10,  
115, 116

atrophy 31

### b

bacterial cellulose (BC) 257

basket-weave orientation 26

benzene 109, 301

block copolymers 38–40

Blood Brain Barrier (BBB) 49

blood vessels 29, 42, 46, 49, 117–119,  
134, 136, 137, 155, 205, 207, 218,  
243, 249, 251, 304, 308, 315, 317,  
324–326

bone-marrow mesenchymal stem cells  
(BM-MSCs) 14, 222, 329

bone morphogenetic protein-2 (BMP-2)  
43, 44, 74, 151, 223, 305, 314, 315

bone tissue engineering (BTE) 223, 313,  
314

bone tissues repair 313–317

### c

cadherins 23, 221, 283

camptothecin 173

carbohydrate 150

CD44 153, 218–221, 224

CD168 219

cell adhesion domains 40

cell adhesion sequences 43–46

cell encapsulation 63, 74, 82, 243, 297,  
331, 340

cell infiltration 41, 42, 304, 341

cell-penetrating peptide (CPP) 49

cell proliferation 30, 31, 44, 45, 205, 224,  
243, 302, 323, 335

chemical crosslinking\chemical  
cross-linking reactions\chemically  
cross-linked hydrogels 39, 41, 48,  
52–55, 63, 66, 75, 225, 236, 333

chemiluminescence (CL) 165

- cholesterol 162, 180, 182  
 chronic obstructive pulmonary disease (COPD) 14  
 circulating tumor cells (CTC) 282  
 cisplatin 173, 177, 180, 182  
 cladding effect 257–259, 261, 262  
 click methodology 39  
 coaxial sheath 235, 237, 239  
 co-culturing system 249, 250  
 collagen 334  
   architecture 26–29  
   cross-linking 29  
   fibril diameter 27–28  
   fibril packing and crosslinking 28–29  
   orientation 26–27  
   scaffolds 29–33  
   sources 25  
   structure of 25  
 collagen-like peptides (CLPs) 118  
 contrast agents (CAs) 165, 169  
 cornea 29, 113, 117–118, 335  
 critical limb ischemia (CLI) 53  
 crosslinking methods 64  
 2-cyanobenzothiazole (CBT) 165, 166, 169
- d**
- decellularization 9, 14, 15  
 dental pulp stem cells (DPSCs) 130, 221  
 dephosphorylation reaction 75  
 deprotonation state 107, 111  
 detergent-enzymatic treatment (DET) 8, 11, 13  
 diabetes mellitus type 2 48  
 diabetic wounds 70, 206–209, 211, 325, 327–330, 341, 342  
 3,4-dihydroxyphenylalanine (DOPA) 106  
 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) 171  
 diphenylalanine (FF) 109, 128  
 dipole-dipole self-assemblies 195, 196  
 direct laser writing 241, 242
- discoidal polymeric nanoconstructs (DPNs) 285, 286  
 DNA polymerases 80–82  
 docetaxel (DTXL) 282, 284  
 double-channel microfluidic chips 277, 281–284  
 DRIR 41  
 DRIR-ELR 42  
 drug delivery 56, 66, 77, 81, 82, 135, 137–139, 173–175  
 drug-loaded scaffolds 32–33  
 drug release 72, 73, 81, 137, 256, 257, 332  
 ductal carcinoma *in situ* (DCIS) 281  
 dynamic covalent chemistry (DCC) 44  
 dynamic granular hydrogels 301  
 dynamic reciprocity 7
- e**
- elastase-sensitive domains 44, 45  
 elastin-like polypeptides (ELPs) 38, 45  
 elastin-like protein-hyaluronic acid (ELR-HA) 44  
 elastin-like recombinamers (ELRs) 37–56, 119  
 electrospinning 27, 46, 110, 111, 199, 202  
 enzymatic crosslinking hydrogels 66–75  
 enzyme-instructed self-assembly (EISA) 75, 161, 175, 177–189  
 epidermal growth factor receptor (EGFR) 224, 225  
 epigallocatechin-3-gallate (EGCG) 223  
 equilibrium swelling theory 3  
 expandable polytetrafluoroethylene (ePTFE) 118  
 extracellular matrix (ECM)/development/growth factors/in homeostasis/hydrogels/proteins 6–8, 10–18, 32, 243, 276–277
- f**
- fibrin 14, 45, 73, 75, 209, 277, 281, 285, 327, 332, 334–335  
 fibroblasts growth factors 48, 49, 74, 151, 327

- Fick's diffusion laws 234
- 9-fluorenylmethyloxycarbonyl (Fmoc) 128
- g**
- gadolinium-containing nanoparticles (GdNPs) 167
- galactose oxidase (GalOx) 70, 223
- $\gamma$ -glutamyltranspeptidase (GGT) 166
- gelatin 5, 14, 18, 72–74, 200, 222, 249, 258, 298, 305, 309, 311, 315, 334, 339, 340
- gelatin-methacrylate (GelMA) 224, 249, 254, 255, 301
- genipin 46
- glioblastoma cells 49
- glioblastoma, treatment 49
- glucagon-like-peptide 1 (GLP-1) 48
- glucose oxidase (GOx) 70, 207, 253
- glucuronic acid (GlcA) 217, 219, 220
- glycopeptides, supramolecular assemblies of 149–156
- glycoproteins 6–8, 149–151, 153, 155, 217, 219, 276
- glycosaminoglycans (GAGs) 7, 8, 10, 11, 15, 130, 150, 151, 154, 155, 217
- Good Manufacturing Protocol (GMP) 1, 6, 16
- GOX/HRP catalytic system 71
- granular hydrogels 297, 299
- MAPs assembly 300–304
- modularity and multifunctionality in 305–306
- granulation tissue 136, 137, 200, 205, 326
- GTAR 41 (AU: Expansion not found in the book)
- h**
- $\beta$ -hairpin peptides 129
- hemostasis 206, 323, 325–326, 334
- heparan sulfate proteoglycan 2 7
- hepatoblastoma (HepG2) cells 12, 169, 170, 183, 184, 186, 250
- hierarchically organized biomaterials
- high resolution microscopy 115
- polarized light microscopy 113–114
- small angle X-ray scattering 115–116
- hierarchical materials 97
- hierarchical self-assembly 98–108, 112
- homopolymeric natural hydrogels 5
- horseradish peroxidase (HRP) 67–72, 82, 207, 223, 224, 253
- Hüisgen reaction 39
- human aortic endothelial cells (HAECs) 49
- human elastin-like polypeptide 53
- human embryonic stem cell (hESC) 4, 12, 334
- human hepatocellular carcinoma (HCC) 12, 13
- human induced pluripotent stem cells (hiPSCs) 4, 6, 12, 221, 225
- human mesenchymal stem cells (hMSCs) 43, 44, 305, 309, 312, 314, 315, 317
- human umbilical vein endothelial cells (HUVECs) 12, 13, 45, 74, 133, 250, 252, 281, 283, 309, 311
- hyaluronan/hyaluronic acid (HA) 5 14, 67, 256, 277, 284, 285, 317, 327, 332, 334, 338, 340
- in biological tissues and fluids 218
- as signaling molecule/signal-transduction 218–220
- 3D cancer models 224–226
- for tissue engineering 220–223
- viscosupplementation 218
- hybrid hydrogels 45, 133, 250, 256, 332, 333, 339–340
- hyperbranched polymer 336–340
- hydrodynamic 235, 237, 239
- hydrogelators 71, 75, 77, 79, 80, 82, 106, 128, 134, 138, 177, 178, 184, 188
- hydrolases 75–80
- hydroxyphenylpropionic acid (HPA) 67
- hyperglycemia 49, 206, 207, 326, 327

**i**

idiopathic pulmonary fibrosis (IPF) 14  
 immersed boundary methods (IBM) 287  
 immersed finite element methods (IFEM)  
 287  
 Indocyanine green (ICG) 225  
 induced pluripotent stem cells (iPSCs)  
 4, 183, 329  
 injectability 299–300  
 interpenetrating polymer networking  
 (IPN) 339  
 inverse temperature transition (ITT) 38  
 Isogeometric analysis (IA) 287  
 isopropyl alcohol (IPA) 256

**j**

jammed state 298

**k**

K9-C-peptide 49

**l**

laccase 71–73  
 $\beta$ -lactamases 75, 78, 80, 82  
 lipid rafts 162, 164, 183  
 lower critical solution temperature  
 (LCST) 3, 337  
 Lymphatic Vessel Endothelial  
 hyaluronan receptor 1 (LYVE-1)  
 220  
 lysyl oxidase (LO) 8, 25, 67

**m**

macroscale actuators 256  
 magnetic anisotropy 109  
 magnetic orientation 109  
 magnetic resonance imaging (MRI) 161,  
 162, 165, 170, 189  
 Matrigel 4–6, 10, 13, 15, 16, 33, 172, 277,  
 282–284  
 matrisome 6, 17  
 matrix assisted laser desorption/  
 ionization (MALDI) mass  
 spectrometry 166

matrix metalloprotease (MMP) 5, 7, 51,  
 74, 78, 80, 82, 118, 137, 138,  
 187–189, 206, 221, 222, 225, 304,  
 305, 314, 326–328  
 mechano-growth factor (MGF) 31  
 mesenchymal stem cells (MSCs) 13, 14,  
 44, 72, 130, 133, 153, 187, 221, 222,  
 305, 309, 312, 314, 315, 317, 329,  
 332  
 metal-organic frameworks (MOFs)  
 261  
 micelle-like particles 38  
 Michael addition 63, 67, 72, 73, 224, 336,  
 337, 339–342  
 microbial TG (mTG)-mediated  
 crosslinking 74  
 microbial transglutaminase (mTGase)  
 53, 74  
 microfluidic chips 275, 276  
 microfluidic 3D bioprinting 251, 252  
 microfluidics 233–234, 242–257  
 microfluidic spun hydrogel 243,  
 249–253, 257  
 microfluidic tissue/organ-weaving 250  
 microfluidic wet spinning 234–242  
 microgrooved fibers 249  
 microparticle assembled nanofibrous  
 (MANF) 315, 317  
 microporous annealed particle (MAPs)  
 297, 300–306, 308, 309, 311–315,  
 317, 318  
 micro-scale actuators 255  
 Mitogen-activated protein kinase (MAPK)  
 219  
 molecular self-assembly 79, 98, 120, 161,  
 186, 188  
 mucoadhesives 52, 63  
 multidomain peptide (MDP) 106, 111,  
 119, 135, 136, 155  
 multi-hydrogel microparticles (HMPs) 296  
 murine intestinal stem cells (mISCs) 4  
 muscle cell 24, 73, 119  
 myeloperoxidase (MPO)  
 206, 208, 212

**n**

N-acetylglucosamine (GlcNAc) 108, 151, 153, 217  
 nanofibrous gel/nanofibrous hydrogel formation 136, 153  
 nanoparticles 284–287  
 natural hydrogels 5–6, 18  
 Navier-Stokes equation 233, 287  
 neovascularization 46, 70, 205, 311, 315, 329, 341  
 neuronal stem cells (NSCs) 47  
 nitrobenzofurazan (NBD) 162, 164, 175, 177, 180, 186  
 N-palmitoyl-Gly-Gly-Gly-His-Gly-Pro-Leu-Gly-Leu-Ala-Arg-Lys-CONH<sub>2</sub> 188  
 nuclear magnetic relaxation dispersion (NMRD) 166, 167

**o**

ocular drug delivery 50, 52  
 OpenPolScope method 113  
 optical fibers 257–263  
 optical imaging 161–165  
 optical sensors 206, 253  
 organ-on-a-chip technology 276  
 ovine carotid arteries (OCA) 45  
 ovine umbilical arteries (OUA) 45  
 oxidoreductases 67–73

**p**

paclitaxel (PTX) 137–139, 281  
 peptide amphiphile (PA) 106, 133, 134, 155  
 peptide-modified transfersomes (PTX-CT) 137  
 peroxidases 67, 72  
 phosphatase 43, 75, 77, 79, 82, 112, 138, 162, 189, 190, 207  
 phosphotyrosine 162, 164  
 photoacoustic imaging 161, 162, 169, 171–173, 189  
 photoradiation-controlled intratumoral depots (PRCITD) 54

physical crosslinking\physically cross-linked ELR-based hydrogels 48–52, 65  
 plasma oxidase (PO) 67  
 polarized light microscopy 113–114  
 poly(2-hydroxyethyl methacrylate) (PHEMA) 200, 202, 208, 210, 211, 335  
 poly(3,4-ethylenedioxythiophene) (PEDOT) 257  
 poly(carboxybetaine acrylamide) (PCBAA) 198, 200–202, 209  
 poly(carboxybetaine-co-methyl methacrylate) 198, 199  
 poly(CMB-r-BMA) 198, 199  
 poly(cyclopentadithiophene-alt-benzothiadiazole) 171  
 poly(dimethyl siloxane) (PDMS) 107, 110, 111, 237, 239, 240, 277, 280, 282  
 poly(ethylene glycol) (PEG) 3, 4, 37, 41, 67, 72–75, 195, 196, 204, 205, 221, 224, 258, 259, 285, 302, 312, 314, 332, 335–337, 339–341  
 poly(ethylene terephthalate) (PET) 118, 198, 199  
 poly(methyl methacrylate) (PMMA) 241, 258  
 poly(n-butyl methacrylate) (PBMA) 198  
 poly(sulfobetaine methacrylate) (PSBMA) 198–200, 202–205, 208, 209, 211, 212  
 poly(vinyl alcohol) (PVA) 3, 73, 256, 258, 332, 335  
 polycarboxybetaines (PCB) 196, 198–202, 206–209, 212  
 poly(ethylene glycol) dimethacrylate (PEGDMA) 204, 205  
 polydimethylsiloxane (PDMS) 105, 107, 110, 111, 237, 239, 240, 277, 280, 282  
 polyethylene terephthalate (PET) 118, 198, 199  
 poly(ethylene glycol-vinyl sulfone) (PEG-VS) 302, 303, 306, 312

- polymerase chain reaction (PCR) 4, 81  
 polymer degradation 41  
 polysulfobetaines (PSBs) 196, 202–205,  
 208–212  
 polyzwitterions (PZI) 195, 196  
     wound management 197  
 porcine small intestinal mucosa-  
     submucosa (pSIS) 15, 16, 18  
 precursor peptide-lipid 188  
 protease operated depot (POD) 48  
 protein tyrosine phosphatase (PTP1B)  
     162  
 proteoglycans 6–8, 10, 28, 149–151, 154,  
     217, 221, 276, 327  
 protonation state 107, 111
- q**
- quantitative image analysis 113  
 quantum-dots (QDs) 261, 262
- r**
- Rabbit mesenchymal stromal cells  
     (rMSCs) 44  
 radiation therapy 49  
 RAFT polymerization 341  
 random closed packing configuration  
     298  
 rational molecular design 98, 100  
 Rayleigh scattering theories 261  
 reactive oxygen species (ROS) 49, 54, 55,  
     171, 175, 206, 223, 311,  
     326, 342  
 Receptor for HA-Mediated Motility  
     (RHAMM) 219, 220, 224  
 Receptor Tyrosine Kinase (RTK's) 219  
 reepithelialisation 341  
 regenerative medicine (RM) 15, 16, 24,  
     27, 37, 39, 40, 42, 56, 63, 64, 66, 67,  
     75, 77, 81, 150, 220, 223, 226, 250,  
     251, 334, 339  
 Reynolds number (Re) 233, 234  
 RGD 4, 5, 7, 41, 43–47, 118, 119, 130,  
     133, 134, 151, 155, 221, 222, 224,  
     300  
 RGDS 118, 314  
 rheometry 10
- S**
- salt-leaching 40  
 sarcoma cell line 5  
 scanning electron microscopy (SEM) 10,  
     115, 174, 189, 190, 203, 283  
 Schiff base 67, 72, 73  
 self-assembling nanofibers 110  
 self-assembling peptide 47, 108, 113,  
     115, 117–120, 137, 150–154,  
     175  
 self-assembling peptide-saccharide  
     151–154  
 SELP-815K 51  
 semiconducting polymer nanoparticle  
     (SPN)-based probe 169  
 semi-IPN 339  
 seven elastin-like blocks (GVGVP) 47  
 shear forces 111  
 silk-elastin-like co-recombinamer (SELR)  
     39, 43, 50, 51  
 silk fibroin (SF) 39, 43, 46, 50, 133, 221  
 single channel microfluidic chips  
     277–282  
 single-fiber scaffolds 243, 248–249  
 single-walled carbon nanotubes (SWNTs)  
     169, 171  
 skeletal muscle 24, 31, 119–120, 251  
 small angle X-ray scattering (SAXS) 115,  
     116  
 smooth muscle cells (SMCs) 24, 73, 118,  
     119, 249  
 sodium deoxycholic acid (SDC) 12–15  
 soft lithography 110, 111, 237, 239–241,  
     263, 277, 282  
 sonication-assisted solution embossing  
     106, 107  
 sortase A (SrtA) 72  
 spinneret 235, 237, 240–242  
 (3-(2'-spiroadamantyl)-4-methoxy-4-  
     (3''-phosphoryloxyphenyl)-1,2-  
     dioxetane (AMPPD)) 165

- stem cells 4, 13, 14, 18, 43, 47, 70, 72, 111, 118, 120, 130, 133, 153, 154, 218, 220–222, 295, 305, 317, 318, 323–343
- strain-promoted azide-alkyne cycloaddition reaction (SPAAC) 41
- strain sensors 253, 255, 262
- stromal vascular fraction (SVF) 46
- subtractive manufacturing methods 241, 242
- supramolecular hydrogels 72, 75, 77, 79–82, 106, 109, 127, 128, 130, 139, 188
- supramolecular systems 151, 153–155, 186
- surface-enhanced Raman spectroscopy (SERS) 260, 262, 263
- synthetic hydrogels 3–5, 259, 333, 335–339
- synthetic peptides 98
- t**
- tetrakis(hydroxymethyl)phosphonium chloride (THPC) 47
- tetrapeptide (FFYK) 128, 177
- tetrazine (Tet) 223, 301, 314
- TGF- $\beta$ 1\transforming growth factor- $\beta$  (TGF- $\beta$ ) 7, 199, 305, 308, 315, 327, 341
- thermolysin 75, 78, 80, 82
- thermoplastic polymers 241
- thermore sponsiveness 38, 39, 226
- Thiol-ene click Michael addition 340
- 3D cell scaffolding 129–131
- tissue engineering 220–223
- tissue engineering and regenerative medicine (TERM) 24, 39, 220, 226, 295–299, 304, 305, 308, 312, 313, 317, 318, 334
- tissue plasminogen activator (tPA) 41, 285, 286
- tissue plasminogen activator-discoidal polymeric nanoconstructs (tPA-DPNs) 285–286
- tissue regeneration 15, 18, 40, 42, 43, 56, 72, 74, 117, 133, 139, 205, 223, 249, 329, 341
- transferases 13, 73–75, 153
- transglutaminase (TG)\transglutaminase 2 (TGase2) 8, 49, 71, 73–75
- transition temperature (Tt) 38, 39
- transmission electron microscopy (TEM) 115
- tris(2-carboxyethyl)phosphine (TCEP) 166
- $\beta$ -[tris(hydroxymethyl)phosphine] propionic acid (THCC) 53
- “Trojan Horse” approach 175
- Troll-Like Receptors (TLRs) 218
- tropocollagen 25
- turbidimetric assays 10
- 2D/3D cell scaffolding 129–131
- 2D microfabrication technique 119
- type-I collagen 110, 248
- tyramine 67, 72, 221, 339
- tyrosinase 67, 72, 82
- u**
- ultrasound 49, 99, 112
- undifferentiated stem cells 329
- urokinase plasminogen activator (uPA) 41
- UV photo-crosslinking method 339
- v**
- vascular endothelial growth factor (VEGF) 14, 32, 44, 45, 119, 133–135, 155, 221, 281, 311, 314, 315, 327, 329, 330
- vascularization 308–311
- vasculogenesis 327, 341
- viscosupplementation 218, 223
- void spaces and microporosity 304, 305

**W**

- wound dressings 71, 72, 82, 136, 195–212, 253, 257
- wound healing 134, 137
  - adipose-derived stem cells for 329–330
  - clinical needs for 323
  - current limitations 330
  - hamostasis 325–326
  - inflammation processes 326
  - materials 332
  - pathology 323–328
  - proliferation 326–328

- remodelling 328

- stem cells 328–330

- wound management 18, 70, 73, 197, 198, 203, 207, 323, 324, 331

**X**

- xenogeneic material 3
- X-ray irradiation 107

**Z**

- zip-clusters 195, 196
- zwitterionic 195, 210, 211













